CLINICAL TRIALS PROFILE FOR PSILOCYBIN
✉ Email this page to a colleague
Clinical Trials for Psilocybin
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00302744 ↗ | Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety | Completed | Heffter Research Institute | Phase 1 | Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain. |
NCT00302744 ↗ | Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety | Completed | Los Angeles Biomedical Research Institute | Phase 1 | Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain. |
NCT00302744 ↗ | Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety | Completed | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Phase 1 | Psychiatric Research Study For Cancer Patients The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain. |
NCT00465595 ↗ | Psychopharmacology of Psilocybin in Cancer Patients | Completed | Heffter Research Institute | Phase 2 | This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices. |
NCT00465595 ↗ | Psychopharmacology of Psilocybin in Cancer Patients | Completed | Johns Hopkins University | Phase 2 | This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices. |
NCT00465595 ↗ | Psychopharmacology of Psilocybin in Cancer Patients | Completed | Sidney Kimmel Comprehensive Cancer Center | Phase 2 | This research is being done to study the psychological effects of psilocybin in cancer patients. Psilocybin is a naturally occurring substance found in some mushrooms that some cultures have used for centuries in religious practices. |
NCT00802282 ↗ | Psilocybin and Spiritual Practice | Completed | Fetzer Institute | Phase 1 | This study will investigate the effects of psilocybin dose and the frequency and intensity of support activities for spiritual practice (e.g., meditation) on a battery of attitudinal and behavioral outcome measures in 75 healthy volunteers who are interested in pursuing a program of spiritual practices with the intention applying spiritual insights and knowledge to everyday life. After screening and study enrollment, each volunteer will be assigned to one of five groups that vary in dose, frequency and intensity of support for spiritual practice, and number of psilocybin sessions (either 2 or 3 sessions). The psilocybin dose manipulation will be double-blind. Volunteers will be told that in each of sessions 1, 2, and 3, he/she could receive a very low, low, moderate, moderately high, or high dose of psilocybin. They will be told that each participant will receive 2 or more dose levels of psilocybin over the 2 or 3 sessions, and all participants will have one or more sessions in which he or she receives a moderately high or high dose of psilocybin. The duration of each volunteer's participation will be approximately 6 to 8 months. Each volunteer will receive several hours of preparation with the study guides in the month prior to the first psilocybin session; the first two sessions will be separated by one month. Various measures will be assessed before, during and immediately after sessions. A battery of longitudinal measures will be evaluated immediately after study enrollment, 3 weeks after the second psilocybin session, and 4 months after the second psilocybin session (6 months after study enrollment). For purposes of controlling expectancies through the 6 month follow-up evaluation, volunteers and guides will not know which volunteers or how many volunteers will be scheduled for a third session. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Psilocybin
Condition Name
Clinical Trial Locations for Psilocybin
Trials by Country
Clinical Trial Progress for Psilocybin
Clinical Trial Phase
Clinical Trial Sponsors for Psilocybin
Sponsor Name